Diaceutics Announces Two Poster Presentations at AMP 2021 Annual Meeting & Expo
10 Septiembre 2021 - 09:40AM
Business Wire
Diaceutics PLC
("Diaceutics" or the "Company")
Diaceutics PLC (AIM: DXRX), the diagnostic commercialization
company, today announced the acceptance of two abstracts for poster
discussion presentation and publication in the November 2021
Journal of Molecular Diagnostics at the Association for Molecular
Pathology (AMP) 2021 Annual Meeting & Expo, which will take
place November 16-20 in Philadelphia, Pennsylvania at the
Pennsylvania Convention Center.
The theme of the meeting this year will be, “Leading Molecular
Medicine Forward”. AMP is the leading organization in the field of
molecular diagnostics, and the annual meeting is widely considered
the premier gathering of molecular professionals. The meeting will
explore how cutting-edge technology and developments in molecular
testing and diagnostics continue to have a major impact on patient
care. These posters are the 9th authored by Diaceutics to be
accepted at major industry meetings in 2021.
Details of the presentations are as follows:
- Abstract Title: US Adoption of Tumor Mutation Burden
(TMB) Testing for Non-Small Cell Lung Cancer (NSCLC) patients in
Clinical Routine Practice: Is now ready for primetime
- Poster Number: ST42
- Abstract Number: 1058086
- Authors: Anthony M Magliocco MD3 and Kenneth J. Bloom MD
FCAP4, Peter V. Riccelli PhD2, Lynn Replogle MBA2, Karen Keating
PhD1, Annie Tapley1, Lauren Parnham1, Lyam Buchanan BSc1, Derry Mae
Keeling BSc1, Susanne Munksted MSc1, Jordan Clark MPhil1
- Abstract Title: Microsatellite Instability/Mismatch
Repair (MSI/MMR): A Cancer Risk Marker Today, Rapidly Evolving into
a Predictive Biomarker for Tomorrow
- Poster Number: ST61
- Abstract Number: 1064193
- Authors: Kenneth J. Bloom MD FCAP4, Anthony M Magliocco
MD3, Charlotte White BSc1, Peter V. Riccelli PhD2, Lauren Parnham1,
Lyam Buchanan BSc1, Annie Tapley BSc1, Derry Mae Keeling BSc1,
Susanne Munksted MSc1, Jordan Clark MPhil1
The research presented as posters at the AMP Annual Meeting from
the abstracts published in the November issue of JMD is embargoed
until the first day of poster presentations at the Annual Meeting
& Expo.
Enabled by DXRX – The Diagnostic Network®, Diaceutics provides
seamless diagnostic testing for Precision Medicines through deep
analysis and disease level-understanding of the testing journey.
Through the extraction of insights from the world’s richest
repository of diagnostic testing data available via its DXRX
platform, the company leverages unique proprietary Disease
Diagnostic Pathways (DDPs®) to identify the best possible testing
journey for patients within a specific disease or disease area.
Discover more at https://www.diaceutics.com and follow the
latest news from Diaceutics on Linkedin @DiaceuticsPLC
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210910005367/en/
Enquiries: Alma PR Caroline Forde Robyn Fisher Kieran
Breheny Matthew Young +44 (0)20 3405 0205
diacuetics@almapr.co.uk
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024